CORRESPONDENCE
/l, with 16% blasts. Bone marrow biopsy confirmed a heavy infiltrate of leukaemic blasts which were positive for CD10 = 90%, CD19 = 90%, HLA-DR = 93%, CD13 = 82%, CD34 = 69% and TdT = 40%. Dual positivity for CD34 and cytoplasmic CD22 was 50% while that for CD34 and myeloperoxidase was negative. Both FISH analysis and RT-PCR for TEL:AML1 were positive. He was given reinduction chemotherapy according to the CALGB ALL protocol 6 from which he attained a CR. He is currently undergoing an autologous stem cell transplant, since he has no HLA-compatible sibling.
The translocation t(12;21) which gives rise to the TEL:AML1 fusion gene is to date the most common genetic mutation found in newly diagnosed paediatric B-lineage ALL, the incidence ranging between 16-32%.
1-3 TEL:AML1 positive ALL appears to have a peak incidence between 3 and 6 years of age with 70-80% of cases occurring in this age group. 7, 8 Moreover, it is rare in either children older than 10 years of age or adults. 9, 10 The age at diagnosis of the above two patients was somewhat older than reported for the majority of individuals exhibiting the TEL:AML1 transcript, although Trka et al 8 have reported a second incidence peak around 10-12 years of age.
The presence of the TEL:AML1 transcript is currently regarded as a predictor of a favourable outcome since it is associated with a 5-year event-free survival of approximately 90%. [1] [2] [3] [4] [5] In support of this, three studies have reported an incidence of TEL:AML1 among relapsed ALL patients of approximately 10%, a frequency which is significantly lower than that found at initial diagnosis. 4, 11, 12 In contrast, however, two recent studies in relapsed paediatric ALL have questioned the favourable prognosis afforded by TEL:AML1. These studies reported an incidence of TEL:AML1 positivity among relapsed patients of 20-24%, a figure which is comparable to that reported at diagnosis. 13, 14 Furthermore, these latter studies showed that TEL:AML1 positivity is associated with a longer remission duration by about 1 year. This suggests that while 5-year disease-free survival has shown to be improved in TEL:AML1 patients, relapse may merely be delayed rather than less frequent. Alternatively, the favourable prognosis conferred by the fussion transcript may critically depend on the efficacy of chemotherapy delivered during induction and maintenance treatment. For children with acute lymphoblastic leukaemia (ALL) who achieve complete remission (CR) with combination chemotherapy, the risk of very late relapse after more than 10 years in CR is approximately 1%. 15 These relapses have been shown by molecular techniques to involve re-emergence of the original clone which can remain dormant for long periods of time. 15 The two patients described above are the first reported cases of TEL:AML1-positive individuals to relapse more than 10 years after their initial remission was achieved. While we do not have access to RNA from the original leukaemic cells in either case, nevertheless, since TEL:AML1 fusion transcripts are very rarely encountered in adult ALL, the relapses are highly likely to represent reactivation of the original leukaemic clone. Taken together, these data suggest that a conventional follow-up period of 4-5 years may be too short to assess final outcome of patients with B-lineage ALL, and in particular those carrying the TEL:AML1 fusion gene.
Mutations of the BCL10 gene are not associated with the blast crisis of chronic myeloid leukaemia

TO THE EDITOR
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder associated in over 95% of the cases with the presence of the BCR-ABL hybrid gene in multipotential haemopoietic precursors. BCR-ABL encodes a 210 kDa fusion protein with enhanced tyrosine kinase activity 1,2 and may underlie most if not all phenotypic abnormalities of the chronic phase (CP) of CML.
3 The invariable evolution of the disease to a fatal blast crisis (BC), often preceded by a transitional period called accelerated phase (AP), is believed to be due to acquisition of additional genetic changes in the leukemic clone. 4 However, the few known abnormalities 5-8 account for less than 30% of the BC and the cause for the drastic phenotypic change of the disease in the majority of CML patients is still unknown. Since no assay that reliably discriminates between the genotypes of CP and BC cells has yet been developed, the search for causative abnormalities has concentrated on the testing of relevant candidate genes. These have generally been selected among genes that (1) are associated with essential cellular pathways such as control of the cell cycle, differentiation or apoptosis, and/or (2) have been implicated in other malignancies.
The BCL10 gene has been recently cloned 9,10 as the translocation partner of the immunoglobulin heavy chain (IgH) locus in the t(1;14)(p22;q32) chromosomal translocation, an abnormality associated with low-grade mucosa-associated lymphoma tissue (MALT)-B cell lymphomas. Located on chromosome 1p22, BCL10 shows recurrent breakpoints in the 5Ј region, which fuses to the J6 region of the IgH gene in a head to head fashion on the derivative chromosome 14. The BCL10 gene is the cellular homolog of the equine herpesvirus-2 E10 gene. The BCL10 protein, like E10 and many others that are involved in apoptotic processes, contains a CARD at its amino-terminus and has been shown to be capable of inducing apoptosis. 9, 10 In addition to its involvement in the t(1;14) of MALT-B lymphomas, BCL10 was initially reported as a frequent target gene for mutation in various neoplasms, including other types of lymphoma and non- haematologic malignancies. 9 The latter findings have however been unconfirmed in several recent studies. [11] [12] [13] [14] [15] [16] In this study, we have investigated the potential involvement of BCL10 gene mutations in the blastic transformation of CML by mutational analysis of CML cell lines and patient samples. We show here that BCL10 is a highly polymorphic gene, but that no functional mutation or increased frequency of specific allelotypes is associated with CML.
Fifty-six patients with CML in blast crisis (19 myeloid, 24 lymphoid, 13 of unknown lineage) and one patient in accelerated phase were included in the present study. Total leucocyte DNA was isolated from heparinized peripheral blood samples after red cell lysis by standard methods. Genomic DNA from 13 CML (AR230, BV173, CMLT-1, EM2, EM3, GDM1, K562, KCL22, KU812, KYO1, LAMA-84, MEG-01, NALM-1) and one acute lymphoblastic leukaemia (ALL) (SD-1) cell lines was also analysed. Control DNA from 92 normal subjects was extracted from peripheral blood leucocytes or buccal epithelium. All specimens were obtained after informed consent.
The complete coding region of the BCL10 gene was amplified in five different polymerase chain reactions (PCR) encompassing exon 1 and two overlapping fragments for each exon 2 and 3 (Figure 1 ). The PCR primers were based on those described elsewhere, 9 except for some slight modifications (Table 1) . Each reaction was seeded with 50-100 ng genomic DNA and amplification was carried out for 30 cycles on a MJ Research thermal cycler (MJ Research, GRI, Essex, UK) under conditions tested as suitable for each primer pair (Table 1) . Composition of the PCR reaction and thermocycling parameters were essentially as previously described.
17 For single-strand conformation polymorphism (SSCP) analysis, the PCR products were labeled with ␣ 32 P-dCTP using three additional cycles of amplification, heatdenatured and electrophoresed on 6-8% polyacrylamide/glycerol gels. Abnormally migrating bands were excised from the gel, purified, reamplified and subcloned into a pCR2.1 TA cloning vector (Invitrogen, Groningen, The Netherlands). Clones were further selected by electrophoresis on polyacrylamide/glycerol gels and those with differently migrating bands were sequenced with fluorescently labelled M13 primers.
No leukaemia-associated BCL10 mutation was observed in any of the CML cell lines or patient samples studied. For the exon 1-including 184-bp fragment, four distinct allelic variants represented by five differently migrating bands were found. Two of these variants were
